



Integral BioSystems LLC Positions Itself as a Key Player in Ophthalmic Drug Delivery

Boston-area specialty drug delivery CRO Integral BioSystems LLC positions itself as a key player in ophthalmic topical and injectables formulation development

BEDFORD, MASSACHUSETTS, USA, August 19, 2016 /EINPresswire.com/ -- For the last five years, [Integral BioSystems LLC](#) has worked diligently to establish its credibility as an expert ophthalmic drug delivery house for its role in formulation development, CMC consulting, analytical method development and methods qualification, as well as scale-up process engineering.

For companies seeking to develop ophthalmic products, Integral BioSystems provides expertise and know-how in developing both front-of-the-eye and back-of-the-eye products. For front-of-the-eye products, Integral scientists have solved development challenges ranging from stabilizing highly labile compounds to solubilizing compounds highly insoluble in water. For delivery to the posterior segment of the eye, Integral BioSystems' expertise in developing drug-encapsulated sustained release injectable PLG microspheres has resulted in a number of clinical stage products that have ranged from water-soluble peptides to water-insoluble small molecules such as anti-inflammatories.

The company has strategically and systematically built up its capabilities to be aligned with ophthalmic product development by offering services in pre-formulation, formulation development, corneal permeability, dissolution testing, in-vitro release studies, analytical method development, stability monitoring, container closure selection, process engineering and scale-up. As part of the push to expand the company's capabilities, Integral is now offering bioanalytical services made possible by its recent acquisition of state-of-art mass spectrometry instrumentation.

For companies seeking to develop a new product that is using a re-purposed drug, Integral offers its innovative delivery systems as licensable technologies to build value into prospective clients' drug products through a 505b2 regulatory strategy. For companies seeking product life cycle management, Integral can help them quickly ascertain if Integral's innovations can provide the desired improvements. With multiple billion dollar drug products going off-patent, this presents a cost effective way to develop an extended product life cycle with novel IP. In this manner, Integral will offer its insight and technological innovations in ocular drug delivery to strategize and improve the customer's product portfolio. To this effect, Integral BioSystems has been a key development partner for both innovator and generic companies.

About Integral BioSystems

Integral BioSystems is a specialty drug delivery contract research organization that offers an integrated, practical approach to formulation development projects for both small molecule and large molecule drug candidates. Offering contract services to pharmaceutical companies to develop drug products through its CMC offerings in analytical method development, formulation development, process development, scale-up and technology transfer, the company also partners with pharmaceutical companies to co-develop products based on its proprietary pharmaceutical delivery systems.

Dave Karasic

Integral BioSystems, LLC
781-275-8059
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2016 IPD Group, Inc. All Right Reserved.